Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | F12 | P00748 | 1/20 | 0.42 |
| ▸ | F7 | P08709 | 1/20 | 0.42 |
| ▸ | F3 | P13726 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12285402 | 1.00 | MAPT (0.42) | MAPTBLMRECQLTSHRHSD17B10 | |
| SCHEMBL1839902 | 1.00 | MAPT (0.42) | MAPTBLMRECQLTSHRHSD17B10 | |
| SCHEMBL14507331 | 0.79 | HDAC1 (0.43) | MAPTBLMRECQLTSHRHSD17B10 | |
| SCHEMBL11124453 | 0.77 | METTL3 (0.42) | MAPTALDH1A1ATMMETTL3GAA | |
| SCHEMBL10956171 | 0.77 | LMNA (0.45) | MAPTTSHRHSD17B10L3MBTL1POLB | |
| SCHEMBL11124456 | 0.77 | METTL3 (0.42) | MAPTALDH1A1ATMMETTL3GAA | |
| SCHEMBL10956169 | 0.77 | LMNA (0.45) | MAPTTSHRHSD17B10L3MBTL1POLB | |
| SCHEMBL13762113 | 0.76 | BLM (0.42) | MAPTBLMRECQLTSHRHSD17B10 | |
| SCHEMBL11858226 | 0.76 | TDP1 (0.54) | MAPTBLMRECQLTSHRHSD17B10 | |
| SCHEMBL4240912 | 0.76 | TDP1 (0.54) | MAPTBLMRECQLTSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960419-B2 | Substituted carboxamides | ELI LILLY AND COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| EP-2076502-B1 | SUBSTITUTED CARBOXAMIDES AS GROUP I METABOTROPIC RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20090182025-A1 | SUBSTITUTED CARBOXAMIDES | ELI LILLY AND COMPANY | 2009-07-16 | — | — | US | disclosed |
| EP-2076502-A2 | SUBSTITUTED CARBOXAMIDES AS GROUP I METABOTROPIC RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008103185-A2 | SUBSTITUTED CARBOXAMIDES AS GROUP I METABOTROPIC RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2008-08-28 | — | — | WO | disclosed |
| WO-2007058942-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| WO-2007056468-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| EP-0129407-A2 | Improvements in and relating to (3-aryl-5-isothiazolyl)ureas | ELI LILLY AND COMPANY (US) | 1984-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182025-A1 | SUBSTITUTED CARBOXAMIDES | CNR2, TRPV1, CNR1 | MAPT 1765/4885BLM 4389/4885RECQL 4107/4885 |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | CHEK1, CHEK2, CDKN1A | MAPT 1927/4885BLM 927/4885RECQL 1008/4885 |
| US-20070105864-A1 | Methods for inhibiting protein kinases | PIM1, PIM2, PIM3 | MAPT 2249/4885BLM 2400/4885RECQL 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.